

**S3 Table.** Demographic and clinical characteristics in stage II NPC patients

Characteristic	IMRT+CT (n=50)	IMRT alone (n=96)	p-value
<b>Age, median (range, yr)</b>	44 (22-73)	46 (21-76)	0.080
<b>Sex</b>			
Male	38 (76.0)	70 (72.9)	0.687
Female	12 (24.0)	26 (27.1)	
<b>KPS score</b>			
80 points	1 (2.0)	7 (7.3)	
90 points	48 (96.0)	88 (91.7)	0.994
100 points	1 (2.0)	1 (1.0)	
<b>WHO category</b>			
Keratinizing, undifferentiated	4 (8.0)	14 (14.6)	0.251
Non-keratinizing, undifferentiated	46 (92.0)	82 (85.4)	
<b>T stage<sup>a)</sup></b>			
T1	7 (14.0)	23 (24.0)	0.158
T2	43 (86.0)	73 (76.0)	
<b>N stage<sup>a)</sup></b>			
N0	2 (4.0)	20 (20.8)	0.007
N1	48 (96.0)	76 (79.2)	
<b>GTVnx-volume (cm<sup>3</sup>)</b>			
≤ 12.0	11 (22.0)	50 (52.1)	< 0.001
> 12.0	39 (78.0)	46 (47.9)	
<b>CLNs positive</b>			
No	7 (14.0)	70 (72.9)	< 0.001
Yes	43 (86.0)	26 (27.1)	
<b>RLNs positive</b>			
No	14 (28.0)	31 (32.3)	0.594
Yes	36 (72.0)	65 (67.7)	
<b>CCI (points)</b>			
≤ 3	34 (68.0)	61 (63.5)	0.592
> 3	16 (32.0)	35 (36.5)	
<b>Pre-treatment BMI (kg/m<sup>2</sup>)</b>			
< 18.5	3 (6.0)	6 (6.3)	> 0.99
≥ 18.5	47 (94.0)	90 (93.7)	
<b>Pre-treatment PNI</b>			
< 52.0	11 (22.0)	22 (23.7)	0.924
≥ 52.0	39 (78.0)	74 (76.3)	
<b>Pre-treatment NLR</b>			
< 1.8	18 (36.0)	29 (30.2)	0.427
≥ 1.8	32 (64.0)	67 (69.8)	

<b>Pre-treatment LDH (U/L)</b>			
< 240	48 (96.0)	91 (94.8)	> 0.99
≥ 240	2 (4.0)	5 (5.2)	

BMI, body mass index; CCI, Charlson comorbidity index; CLNs, cervical lymph nodes; CT, chemotherapy; GTVnx, gross tumor volumes of nasopharynx; IMRT, intensity-modulated radiation therapy; KPS, Karnofsky performance status; LDH, lactate dehydrogenase; NLR, neutrophil to lymphocyte ratio; NPC, nasopharyngeal carcinoma; PNI, prognostic nutritional index; RLNs, retropharyngeal lymph nodes; WHO, World Health Organization. <sup>a)</sup>According to the American Joint Committee on Cancer, 8th edition.